NASDAQ:INDP Indaptus Therapeutics Q2 2026 Earnings Results & Report $2.82 -0.31 (-9.90%) Closing price 04:00 PM EasternExtended Trading$2.82 0.00 (0.00%) As of 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Indaptus Therapeutics beat analyst earnings expectations in its Q2 2026 results, released August 13, 2026. The company reported EPS of -$0.02 versus the -$1.57 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 13, 2026TimeBefore Market OpensConference Call7:00 AM ET Indaptus Therapeutics EPS ResultsActual EPS-$0.02Consensus EPS -$1.57Beat/MissBeat by +$1.55One Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersIndaptus Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Indaptus Therapeutics Q2 2026 Earnings FAQ Did Indaptus Therapeutics beat earnings estimates for Q2 2026? Indaptus Therapeutics (NASDAQ:INDP) reported earnings of -$0.02 per share for Q2 2026, beating the consensus estimate of -$1.57. The report was announced on Thursday, August 13, 2026. Indaptus Therapeutics Earnings HeadlinesIndaptus Therapeutics Reports Third Quarter 2026 Financial Results and Corporate UpdateNovember 13, 2026 | quiverquant.comQIndaptus Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateNovember 13, 2026 | globenewswire.comURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.November 20 at 1:00 AM | Paradigm Press (Ad)Indaptus Therapeutics Extends Timeline for Private Placement FinancingSeptember 30, 2026 | tipranks.comIndaptus Therapeutics Shares Rise After Entering $24 Million Private PlacementSeptember 10, 2026 | finance.yahoo.comIndaptus Therapeutics Announces Routine Board Member ResignationSeptember 4, 2026 | tipranks.comSee More Indaptus Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Indaptus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Indaptus Therapeutics and other key companies, straight to your email. Email Address About Indaptus TherapeuticsIndaptus Therapeutics (NASDAQ:INDP) is a clinical-stage biotechnology company developing immunotherapies intended to stimulate the immune system to fight cancer and infectious diseases. Its approach uses proprietary bacterial-based candidates designed to activate multiple immune pathways. The company’s lead candidate, Decoy20, is an investigational immunotherapy made from a mixture of inactivated, non-pathogenic bacteria. Indaptus is evaluating the candidate in clinical research for advanced solid tumors; it has not been established as a treatment for any disease. Indaptus is focused on developing its pipeline rather than marketing approved products. The company is headquartered in the United States, and its publicly described clinical work has included U.S. research sites.View Indaptus Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel ItAirfares Are Up, Flights Are Tight: 3 Airline Stocks Facing a Winter TestHard Drives Were Left for Dead, But Seagate and Western Digital Are SoaringPalo Alto Networks' Q1 Beat Gives Its Stock Rally Another Reason to RunGrand Theft Auto VI Arrives: Why Take-Two Is a Waiting GameWalmart Earnings Change the Narrative as Digital Growth Lifts OutlookWhatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.